DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR MUCINEX DM
» See Plans and Pricing
505(b)(2) Clinical Trials for Mucinex Dm
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00902707 | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | Reckitt Benckiser LLC | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| OTC | NCT00902707 | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | University of North Carolina, Chapel Hill | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| OTC | NCT01114581 | Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection | Completed | Reckitt Benckiser LLC | Phase 2 | 2010-04-01 | The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Mucinex Dm
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00441246 | Phase 4 Study - Mucinex D as Adjunct Therapy | Completed | Adams Respiratory Therapeutics | Phase 4 | 2007-02-01 | The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection. |
| NCT00902707 | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | Reckitt Benckiser LLC | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| NCT00902707 | Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung | Completed | University of North Carolina, Chapel Hill | Phase 1 | 2009-05-01 | The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body. |
| NCT01046136 | Mucinex Exploratory Cold Study | Completed | Reckitt Benckiser LLC | Phase 2 | 2009-12-01 | This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms. |
| NCT01114581 | Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection | Completed | Reckitt Benckiser LLC | Phase 2 | 2010-04-01 | The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections. |
| NCT01202279 | Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI | Completed | Reckitt Benckiser LLC | Phase 4 | 2009-10-01 | The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo |
| NCT01537081 | Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections | Completed | Reckitt Benckiser LLC | Phase 2/Phase 3 | 2011-09-01 | The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by immediate release (IR) guaifenesin (GGE) and do not match approved Mucinex labeling in the U.S. The purpose of this study is to determine whether Mucinex is effective and non-inferior as compared to placebo and immediate release guaifenesin in the treatment of symptoms of acute upper respiratory infections. This design was required based on EU regulatory guidance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mucinex Dm
Condition Name
Condition MeSH
Clinical Trial Locations for Mucinex Dm
Trials by Country
Clinical Trial Progress for Mucinex Dm
Clinical Trial Phase
Clinical Trial Sponsors for Mucinex Dm
Sponsor Name
